中国药科大学开发的国家Ⅰ类抗肿瘤新药去氧鬼臼毒素获得临床批件
发布时间：2018-10-18 09:30
【摘要】：正由中国药科大学医药化工研究所朱雄、吴葆金研究员负责研发,具有自主知识产权的国家Ⅰ类抗肿瘤新药去氧鬼臼毒素及其注射剂经过长达八年的艰苦努力,日前顺利通过了国家食品药品监督管理总局审批,获得了CFDA颁发的Ⅰ~Ⅲ期药物临床研究批件,这是中国药科大学在创新药研究领域取得的又一重要成果。去氧鬼臼毒素(以下简称DPT)是从中药中提取的有效成分,自然界存在于桃儿七等药用植物中,但含量极微,且在
[Abstract]:The deoxypodophyllotoxin and its injection, a national class I antitumor drug with independent intellectual property rights, is being developed by Zhu Xiong, Institute of Pharmaceutical and Chemical Research, China University of Pharmacy, and Wu Baojin, a researcher in charge of the research and development, after eight years of hard work. The approval of the State Administration of Food and Drug Administration was successfully approved by the State Administration of Food and Drug Administration a few days ago, and the approval of the phase 鈪，
本文编号：2278709
[Abstract]:The deoxypodophyllotoxin and its injection, a national class I antitumor drug with independent intellectual property rights, is being developed by Zhu Xiong, Institute of Pharmaceutical and Chemical Research, China University of Pharmacy, and Wu Baojin, a researcher in charge of the research and development, after eight years of hard work. The approval of the State Administration of Food and Drug Administration was successfully approved by the State Administration of Food and Drug Administration a few days ago, and the approval of the phase 鈪，
本文编号：2278709
本文链接：https://www.wllwen.com/falvlunwen/zhishichanquanfa/2278709.html
